Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...
Androgens can drive prostate cancer growth, thus providing the rationale for using deprivation of androgens as a first line of treatment for prostate cancer. Unfortunately, prostate cancer cells adapt ...
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen ...
Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer at stages where the disease has spread to the bones. However, new research has found that anti-androgen treatment ...
Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial Of 118 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results